AzTrials
AzTrials

Mycosis FungoidesPhase 1/2NCT04541017

Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment

A Phase 1/2 study testing Biospecimen Collection, Computed Tomography and Magrolimab in people with Mycosis Fungoides and Recurrent Mycosis Fungoides, run by National Cancer Institute (NCI) at 18 sites in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

This phase Ib/II trial identifies the best dose and possible benefits and/or side effects of magrolimab when given in combination with mogamulizumab in treating patients with stage IB-IV mycosis fungoides or Sezary syndrome types of T-cell lymphoma that has come back (relapsed) or does not respond to treatment… Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Biospecimen Collection, Computed Tomography and Magrolimab
Could I receive a placebo?
No, everyone receives an active treatment
How many people
8 participants
Where
18 sitesUnited States
Study dates
6 Apr 2021to 24 Oct 2024
Phase
Phase 1/2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Diagnosis of either mycosis fungoides (MF) or Sezary syndrome (SS) by the World Health Organization (WHO) 2016 classification (Swerdlow et al., 2017), stage IB-IV by modified International Society for Cutaneous Lymphomas (ISCL)/ European Organization of Research and Treatment of Cancer (EORTC) classification (Olsen et al., 2011), without large cell transformation (LCT) at the time of screening. Patients with a history of prior LCT are permitted
  • Patients must have had at least one prior course of systemic therapy
  • Age >= 18 years
  • Because no dosing or adverse event data are currently available on the use of Hu5F9-G4 (magrolimab) in combination with mogamulizumab in patients <18 years of age, children are excluded from this study, but will be eligible for future pediatric trials
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
  • Hemoglobin >= 9.5 g/dL and transfusion independence (defined as not requiring more than 2 units of red blood cell [RBC] transfusions during the 4-week period prior to screening)
Show all 26Show fewer
  • Absolute neutrophil count >= 1,000/mcL
  • Platelets >= 75,000/mcL
  • Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) except for subjects with Gilbert's syndrome or genetic equivalent
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional ULN
  • Glomerular filtration rate (GFR) >= 40 mL/min/1.73 m^2 by the Cockcroft-Gault formula
  • Patients must meet the following minimum wash-out window from previous treatments to the first treatment
  • >= 3 weeks for systemic anti-cancer therapies
  • >= 2 weeks for phototherapy, local radiation therapy, topical high potency corticosteroid, topical retinoid, topical nitrogen mustard, or topical toll-like receptor (TLR)-agonist
  • >= 12 weeks for total skin electron beam therapy Participants with rapidly progressive malignant disease may be enrolled prior to completion of the above periods with approval of the protocol director
  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
  • Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression for a minimum of 3 months
  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
  • The effects of Hu5F9-G4 (magrolimab) on the developing human fetus are unknown. For this reason and because monoclonal antibody agents as well as other therapeutic agents used in this trial (mogamulizumab) are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation and continue for 4 months after the last dose of both Hu5F9-G4 (magrolimab) and mogamulizumab. Effective contraception is defined as oral contraceptives, double barrier method (condom plus spermicide or diaphragm plus spermicide) or practice true abstinence from heterosexual intercourse. Women of childbearing potential includes any female who has experienced menarche and has not undergone successful surgical sterilization or is not postmenopausal (defined as amenorrhea >= 12 consecutive months). Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol who are sexually active with women of childbearing potential and who have not had vasectomies must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of Hu5F9-G4 (magrolimab) administration
  • Female patients of childbearing potential must not be nursing or planning to be pregnant and must have a negative urine or serum pregnancy test within 30 days before randomization and within 72 hours before the first administration of study treatment
  • Female patients of childbearing potential must be willing to use one highly effective method of contraception during the study and continue for 4 months after the last dose of study treatment
  • Male patients who are sexually active with a woman of childbearing potential (WOCBP) and who have not had vasectomies must be willing to use a barrier method of contraception (condom plus spermicidal gel) and refrain from sperm donation during the study and for 4 months after the last dose of study treatment. If the partner is pregnant, male patients must use barrier method contraception (condom) during the study and for 4 months after the last dose of study treatment to prevent fetal exposure to study treatment
  • Ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) who have a legally-authorized representative (LAR) and/or family member available will also be eligible
  • Willing to comply with clinic visit schedule and procedures including mandatory biopsies

Who cannot join

  • Prior treatment with Hu5F9-G4 (magrolimab) or any agent targeting CD47-SIRPalpha
  • Prior progression of disease with mogamulizumab
  • Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia and lymphopenia (any grade permitted). Residual peripheral neuropathy must have improved to grade 2 or better
  • Patients who are receiving any other investigational agents
  • Allogeneic hematopoietic stem cell transplant recipients with any graft-versus-host disease within the previous 3 months or requiring immunosuppression
  • Active autoimmune disease that has required systemic immunosuppressive medication within the previous 3 months
Show all 27Show fewer
  • Active herpes simplex or herpes zoster. Subjects on prophylaxis for herpes who have no active signs of active infection, and whose last active infection was more than 6 months ago, may enter the study, and should continue to take the prescribed medication for the duration of the study
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to Hu5F9-G4 (magrolimab), other monoclonal antibodies, or other agents (mogamulizumab) used in study
  • Significant cardiopulmonary disease defined as
  • Acute myocardial infarction within the last 6 months
  • Unstable angina
  • Congestive heart failure New York Heart Association (NYHA) class III-IV
  • Patients with uncontrolled intercurrent illness requiring antibiotics. Patients on prophylactic antibiotics for non-complicated staphylococcus colonization/infection are eligible
  • Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are excluded
  • Patients with psychiatric illness/social situations or substance abuse that would limit compliance with study requirements
  • Pregnant women are excluded from this study because Hu5F9-G4 (magrolimab) is monoclonal antibody agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with Hu5F9-G4 (magrolimab), breastfeeding should be discontinued if the mother is treated with Hu5F9-G4 (magrolimab). These potential risks may also apply to other agents used in this study (mogamulizumab)
  • Patients with RBC transfusion dependence, defined as requiring more than 2 units of RBCs transfused during the 4-week period prior to screening. RBC transfusions are permitted during the screening period and prior to enrollment
  • Patients with prior autoimmune thrombocytopenia, hemolytic anemia or Evans syndrome requiring treatment in the last 12 months
  • Patients on the following medications at the time of enrollment:
  • Immunotherapy or immunosuppressive drugs (e.g. chemotherapy or systemic corticosteroids) EXCEPT for the following:
  • Intranasal, inhaled, or local steroid injection (e.g. intra-articular injection)
  • Systemic corticosteroids at physiologic doses =< 10 mg/day of prednisone or equivalent, if patient has been on a stable dose for at least 2 weeks prior to the first treatment
  • Low and medium potency topical corticosteroids are permitted if patient has been on a stable dose for at least 2 weeks prior to the first treatment
  • Steroids as premedication for hypersensitivity reactions (e.g. computed tomography [CT] scan premedication)
  • Growth factors (granulocyte colony stimulating factor or granulocyte macrophage colony stimulating factor) EXCEPT for erythropoietin and darbepoetin alpha
  • Herbal remedies with immunostimulating properties (e.g., mistletoe extract) or known to potentially interfere with major organ function (e.g. hypericin)
  • Live vaccines are not allowed while participating in the trial. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, Bacillus Calmette-Guerin (BCG), typhoid (oral) vaccine, and intranasal influenza vaccines (e.g., Flu-Mist). However, seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed

Trial locations and contacts

18 sites in 1 country.

18 sites in 1 country

United States18 sites

  • Memorial Sloan Kettering Basking Ridge

    Basking Ridge, New Jersey, 07920

  • Northwestern University

    Chicago, Illinois, 60611

  • Memorial Sloan Kettering Commack

    Commack, New York, 11725

  • City of Hope Comprehensive Cancer Center

    Duarte, California, 91010

  • Memorial Sloan Kettering Westchester

    Harrison, New York, 10604

  • Los Angeles General Medical Center

    Los Angeles, California, 90033

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California, 90033

  • University of Wisconsin Carbone Cancer Center - University Hospital

    Madison, Wisconsin, 53792

  • Memorial Sloan Kettering Monmouth

    Middletown, New Jersey, 07748

  • Memorial Sloan Kettering Bergen

    Montvale, New Jersey, 07645

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone

    New York, New York, 10016

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065

  • NYP/Weill Cornell Medical Center

    New York, New York, 10065

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma, 73104

  • Stanford Cancer Institute Palo Alto

    Palo Alto, California, 94304

  • Washington University School of Medicine

    St Louis, Missouri, 63110

  • Memorial Sloan Kettering Nassau

    Uniondale, New York, 11553

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina, 27157

Other trials in United States

About this study

Official title: A Phase 1b/2 Study of Hu5F9-G4 (Magrolimab) in Combination With Mogamulizumab in Relapsed/Refractory Treated T-Cell Lymphoma

This phase Ib/II trial identifies the best dose and possible benefits and/or side effects of magrolimab when given in combination with mogamulizumab in treating patients with stage IB-IV mycosis fungoides or Sezary syndrome types of T-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Magrolimab and mogamulizumab are monoclonal antibodies that may interfere with the ability of cancer cells to grow and spread. Treatment with magrolimab in combination with mogamulizumab may stabilize cancer for longer period than the usual treatment in patients with relapsed/refractory T-cell lymphoma who have been previously treated.

Read the detailed description

PRIMARY OBJECTIVES:

  1. To characterize the safety and toxicity profile and to determine a safe recommended phase 2 dose (RP2D) of Hu5F9-G4 (magrolimab) when given in combination with mogamulizumab. (Phase I) II. To compare the proportion of patients who achieve a partial or complete response lasting at least 6 months (ORR6) of the combination of Hu5F9-G4 (magrolimab) and mogamulizumab versus mogamulizumab alone. (Phase II)

SECONDARY OBJECTIVES:

  1. To observe and record anti-tumor activity. (Phase I)

II. To compare the efficacy of the combination of Hu5F9-G4 (magrolimab) and mogamulizumab versus mogamulizumab alone with respect to the following endpoints (Phase II):

IIa. Overall response rate (ORR); overall response rate lasting at least 4 months (ORR4); overall response rate lasting at least 12 months (ORR12).

IIb. Duration of response (DOR). IIc. Progression-free survival (PFS). IId. Time to next treatment (TTNT).

EXPLORATORY OBJECTIVES:

  1. To identify potential biomarkers that correlate with response to mogamulizumab and Hu5F9-G4 (magrolimab) including (Phase I and II):

Ia. Expression of CCR4. Ib. Somatic mutations and germline polymorphisms. Ic. Phenotyping of lymphoma and immune microenvironment. Id. Functional assay of phagocytosis.

OUTLINE: This is a phase Ib, dose de-escalation study of magrolimab followed by a phase II study. Patients in the phase Ib study receive treatment as in Arm I. Patients in the phase II study are randomized to Arm I or Arm II.

ARM I: Patients receive magrolimab intravenously (IV) over 2-3 hours weekly during cycles 1-2, then every 2 weeks (Q2W) during cycles 3-12. Patients also receive mogamulizumab IV over at least 60 minutes weekly during cycle 1, then Q2W during cycles 2-12. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo positron emission tomography (PET)/computed tomography (CT) or diagnostic CT, blood sample collection, and may undergo a skin punch biopsy during screening and on study.

ARM II: Patients receive mogamulizumab IV over at least 60 minutes weekly during cycle 1, then Q2W during cycles 2-12. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients who have received at least 2 full treatment cycles and have progressive disease (PD) or have received at least 6 full treatment cycles and have stable disease (SD) may crossover to Arm I. Patients undergo PET/CT or diagnostic CT, blood sample collection, and may undergo a skin punch biopsy during screening and on study.

After completion of study treatment, patients are followed up every 3 months for 2 years.

Being tested
Biospecimen Collection, Computed Tomography, Magrolimab, Mogamulizumab, Positron Emission Tomography
Medical subject headings
Mycosis Fungoides, Sezary Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Biospecimen CollectionProcedure or surgery

    Also called Biological Sample Collection, Biospecimen Collected, Specimen Collection

    Undergo blood sample collection

  • Computed TomographyProcedure or surgery

    Also called CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography

    Undergo PET/CT or diagnostic CT

  • MagrolimabBiological

    Also called Hu5F9-G4, ONO 7913, ONO-7913, ONO7913

    Given IV

  • MogamulizumabBiological

    Also called Immunoglobulin G1, Anti-(CC Chemokine Receptor CCR4) (Human-Mouse Monoclonal KW-0761 Heavy Chain), Disulfide With Human-Mouse Monoclonal KW-0761 Kappa-Chain, Dimer, KM8761, KW 0761, KW-0761

    Given IV

  • Positron Emission TomographyProcedure or surgery

    Also called Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure)

    Undergo PET/CT

  • Punch BiopsyProcedure or surgery

    Also called BIOPSY, PUNCH, Punch Biopsy of Skin

    Undergo skin punch biopsy

Study groups in NCT04541017
Study groupRoleWhat they receive
Arm I (magrolimab, mogamulizumab), Phase Ib and Phase IIExperimentalPatients receive magrolimab IV over 2-3 hours weekly during cycles 1-2, then Q2W during cycles 3-12. Patients also receive mogamulizumab IV over at least 60 minutes weekly during cycle 1, then Q2W during cycles 2-12. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo PET/CT or diagnostic CT, blood sample collection, and may undergo a skin punch biopsy during screening and on study.
Receives: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Biological: Magrolimab; Biological: Mogamulizumab; Procedure: Positron Emission Tomography; Procedure: Punch Biopsy
Arm II (mogamulizumab), Phase IIActive comparatorPatients receive mogamulizumab IV over at least 60 minutes weekly during cycle 1, then Q2W during cycles 2-12. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients who have received at least 2 full treatment cycles and have PD or have received at least 6 full treatment cycles and have SD may crossover to Arm I. Patients undergo PET/CT or diagnostic CT, blood sample collection, and may undergo a skin punch biopsy during screening and on study.
Receives: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Biological: Mogamulizumab; Procedure: Positron Emission Tomography; Procedure: Punch Biopsy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Recommended Phase 2 Dose (RP2D) of Magrolimab When Given in Combination With Mogamulizumab (Phase Ib)

    The phase 1b portion of the trial was designed to determine a RP2D of Hu5F9-G4 (magrolimab) and was planned to enroll 6-18 patients.

    Measured: Up to 4 weeks from the first infusion of magrolimab (priming infusion)

  2. Overall Response Rate at 6 Months (ORR6) (Phase II)

    Will be defined as the proportion of patients who have a partial or complete response to therapy AND a duration of response >= 6 months. Will use a stratified Cochran-Mantel-Haenszel chi-squared test to compare between-group differences in ORR6 proportion. Will also conduct a secondary analysis on the intent-to-treat population (all patients randomized to a therapy and assigned a study number) and an efficacy evaluable set (all patients who received the first 12 weeks of treatment and completed the week 12 response assessment).

    Measured: At 6 months

Secondary outcomes (6)

  1. Overall Response Rate (ORR) (Phase Ib)

    Defined as the proportion of patients who have a partial or complete response to therapy as defined by the global response score.

    Measured: Up to 2 years

  2. Overall Response Rate at 4 Months (ORR4) (Phase II)

    Will be defined as the proportion of patients who have a partial or complete response to therapy AND a duration of response >= 4 months. Will be assessed by the chi-squared method.

    Measured: At 4 months

  3. Overall Response Rate at 12 Months (ORR12) (Phase II)

    Will be defined as the proportion of patients who have a partial or complete response to therapy AND a duration of response >= 12 months. Will be assessed by the chi-squared method.

    Measured: At 12 months

  4. Progression-free Survival (PFS) (Phase II)

    Will be assessed by the Kaplan-Meier method and the log-rank test.

    Measured: From start of treatment to time of progression or death, whichever occurs first, assessed up to 2 years

  5. Duration of Response (DOR) (Phase II)

    Will be assessed by the Kaplan-Meier method and the log-rank test.

    Measured: From the time measurement criteria are met for complete response or partial response (whichever is first recorded) until the first date that recurrence or progressive disease is objectively documented, assessed up to 2 years

  6. Time to Next Treatment (TTNT) (Phase II)

    Will be assessed by the Kaplan-Meier method and the log-rank test.

    Measured: From the start of treatment on this protocol to time of the next anti-neoplastic therapy, assessed up to 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Sep 2020
  2. Study start6 Apr 2021
  3. Primary completion24 Oct 2024
  4. Study completion24 Oct 2024

Why it stopped: Drug supply issues

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Masking
None (open label)
Enrolment
8 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04541017
Sponsor's protocol ID
NCI-2020-06710
Other IDs
NCI-2020-06710, PHII-203, 10384, 10384, UM1CA186717
Status last verified
Sep 2025
First submitted
5 Sep 2020
Last updated
16 Oct 2025
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing Biospecimen Collection, Computed Tomography and Magrolimab in people with Mycosis Fungoides and Recurrent Mycosis Fungoides, run by National Cancer Institute (NCI) at 18 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 26 inclusion and 27 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 16 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 18 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 16 Oct 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Recommended Phase 2 Dose (RP2D) of Magrolimab When Given in Combination With Mogamulizumab (Phase Ib) (time frame: Up to 4 weeks from the first infusion of magrolimab (priming infusion)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04541017.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Oct 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in